Personalized Cancer Vaccines Market Size, Detailed Analysis, Competitive Landscape Forecast To 2026 | Neon Therapeutics, Moderna, Inc., Merck & Co., Inc., Gritstone Oncology, Personalis Inc

Data Bridge Market Research released a new market study on Global Personalized Cancer Vaccines Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. This Global Personalized Cancer Vaccines Market report makes available a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, gross and gross margin.

Get a sample copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-personalized-cancer-vaccines-market

Global Personalized Cancer Vaccines to grow with a substantial CAGR in the forecast period of 2019-2026 Growing rate of prevalence rate of cancer and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market.

Few of the major competitors currently working in the personalized cancer vaccines market are Neon Therapeutics, Moderna, Inc., Merck & Co., Inc., Gritstone Oncology, Personalis Inc, Genocea Biosciences, Inc., F. Hoffmann-La Roche Ltd, CureVac AG, Celldex Therapeutics, BioNTech SE, Advaxis, Inc, and among others.

Market Definition: Global Personalized Cancer Vaccines Market

Personalized cancer vaccines are the type of immunotherapy that boosts the immune system to fight against a cancerous cell. These types of vaccine are tailored to match a patient's particular tumor cell after received cancer related surgery. This vaccine may prevent from cancer, destroy cancer cells and inhibit the growth of tumors cells.

According to the article published in The American Cancer Society, it was identified that the total incidence of cancer in the United States in the year 2018 were1, 735,350 and 609,640 patients die from cancer in the same year. Growing rate of incidence rate of cancer and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market.

Market Drivers

Increases cases of cancer globally
Growing demand of personalized cancer vaccine production
Government initiatives and assistance for cancer related preventions
Robust pipeline of novel therapies under clinical development
Increase in strategic collaboration between the companies

Market Restraints

High cost involved in the treatment
Scientific and major technical challenges for production of personalized cancer vaccine
Inadequate awareness about personalized cancer vaccine in some developing countries

Make an Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-personalized-cancer-vaccines-market

Segmentation: Global Personalized Cancer Vaccines Market

By Cancer Type

Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Prostate Cancer
Cervical Cancer
Glioblastoma
Other

By Mechanism of action Type

Tumor-associated antigens (TAAs)
Tumor-specific antigens (TSAs)
Somatic Mutations in Cancer Pharmacogenomics
Pharmacogenomics towards Genomic Polymorphism

By Biomaker Type

Pharmacogenomic Biomarkers
Prognostic and Predictive Biomarkers
Immune Checkpoint Biomarkers
Others

By Route of administration

Injectables

By End users

Hospitals
Homecare
Specialty Clinics
Others

By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Key Developments in the Market:

In March 2019, Neon Therapeutics, Inc. investigating NEO-PV-01, a novel personalized cancer vaccine cells in a combination with nivolumab that targeting neoantigens and kills their cancer cells.

In September 2016, BioNTech AG and Genentech, Inc. has entered into research collaboration for the development of messenger RNA (mRNA)-based, individualized cancer vaccines for the treatment of broad range of cancer. As per the deal, BioNTech AG receive USD 310 million as a upfront payment and eligible to receive milestone payment.

In June 2016, Moderna, Inc and Merck & Co., Inc entered into research collaboration for the development of mRNA-based personalized cancer vaccines in a combination with keytruda (pembrolizumab) for the treatment of multiple types of tumor. As per the deal, Moderna, Inc. will receive USD 200 million from Merck & Co., Inc. as upfront payment.

Competitive Analysis:

Global personalized cancer vaccines market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of personalized cancer vaccines market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 05: PIPELINE ANALYSIS

Pipeline analysis

PART 06: MARKET SIZING

Market definition

Market sizing

Market size and forecast

PART 07: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

The threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 08: MARKET SEGMENTATION

Segmentation

Comparison

Market opportunity

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation

Regional comparison

North America

South America

Europe

MEA

APAC

Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

PART 16: APPENDIX

List of abbreviations

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-personalized-cancer-vaccines-market

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.